These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 36016946)

  • 61. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
    Kyi C; Postow MA
    Immunotherapy; 2016 Jun; 8(7):821-37. PubMed ID: 27349981
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success.
    Kon E; Benhar I
    Drug Resist Updat; 2019 Jul; 45():13-29. PubMed ID: 31382144
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immune Checkpoint Inhibitors in AML-A New Frontier.
    Thummalapalli R; Knaus HA; Gojo I; Zeidner JF
    Curr Cancer Drug Targets; 2020; 20(7):545-557. PubMed ID: 32316893
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: A meta-analysis of randomized controlled trials.
    Mo DC; Huang JF; Luo PH; Huang SX; Wang HL
    Clin Immunol; 2021 Nov; 232():108876. PubMed ID: 34740840
    [TBL] [Abstract][Full Text] [Related]  

  • 65.
    Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
    Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 67. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
    Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
    Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Metal-organic framework-mediated multifunctional nanoparticles for combined chemo-photothermal therapy and enhanced immunotherapy against colorectal cancer.
    Liu H; Xu C; Meng M; Li S; Sheng S; Zhang S; Ni W; Tian H; Wang Q
    Acta Biomater; 2022 May; 144():132-141. PubMed ID: 35307591
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.
    Petrova V; Arkhypov I; Weber R; Groth C; Altevogt P; Utikal J; Umansky V
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32235439
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Combination of checkpoint inhibitors with other agents as a strategy to improve anti-cancer effect - a glimpse to the future.
    Karamouzis MV; Papavassiliou AG
    Expert Opin Investig Drugs; 2018 Jul; 27(7):569-572. PubMed ID: 29958097
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition.
    Yuan J; Khilnani A; Brody J; Andtbacka RHI; Hu-Lieskovan S; Luke JJ; Diab A; Marabelle A; Snyder A; Cao ZA; Hodi FS
    Eur J Cancer; 2021 Nov; 157():493-510. PubMed ID: 34561127
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Predictive genetic biomarkers in immune checkpoint inhibitors for non-small-cell lung cancer.
    Henriques GT; Barbieri de Souza C; Aguiar PN
    Immunotherapy; 2022 Mar; 14(4):249-257. PubMed ID: 35076285
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
    Cheng AL; Hsu C; Chan SL; Choo SP; Kudo M
    J Hepatol; 2020 Feb; 72(2):307-319. PubMed ID: 31954494
    [TBL] [Abstract][Full Text] [Related]  

  • 75. STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer.
    Shi J; Liu C; Luo S; Cao T; Lin B; Zhou M; Zhang X; Wang S; Zheng T; Li X
    Cell Immunol; 2021 Aug; 366():104384. PubMed ID: 34182334
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy.
    Li H; Zhao A; Li M; Shi L; Han Q; Hou Z
    Front Immunol; 2022; 13():1046755. PubMed ID: 36569893
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immune checkpoint inhibitors combined with HER-2 targeted therapy in HER-2 positive gastroesophageal cancer.
    Aisa A; Weng S; Li X; Zhang D; Yuan Y
    Crit Rev Oncol Hematol; 2022 Dec; 180():103864. PubMed ID: 36332788
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Encapsulation of Platinum Prodrugs into PC7A Polymeric Nanoparticles Combined with Immune Checkpoint Inhibitors for Therapeutically Enhanced Multimodal Chemotherapy and Immunotherapy by Activation of the STING Pathway.
    Gao X; Lei G; Wang B; Deng Z; Karges J; Xiao H; Tan D
    Adv Sci (Weinh); 2023 Feb; 10(4):e2205241. PubMed ID: 36504435
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer.
    Ding Y; Wang Z; Zhou F; Chen C; Qin Y
    Front Oncol; 2022; 12():987302. PubMed ID: 36248998
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Unraveling the Therapeutic Benefit of Sequenced Chemo-immunotherapy.
    Vignali PDA; Luke JJ
    Clin Cancer Res; 2024 May; 30(9):1705-1707. PubMed ID: 38372597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.